Juno Therapeutics Inc (NASDAQ:JUNO) EVP Robert Azelby Sells 29,131 Shares

Juno Therapeutics Inc (NASDAQ:JUNO) EVP Robert Azelby sold 29,131 shares of the company’s stock in a transaction dated Wednesday, January 17th. The stock was sold at an average price of $68.61, for a total value of $1,998,677.91. Following the completion of the sale, the executive vice president now owns 73,330 shares in the company, valued at approximately $5,031,171.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Robert Azelby also recently made the following trade(s):

  • On Thursday, February 8th, Robert Azelby sold 3,497 shares of Juno Therapeutics stock. The shares were sold at an average price of $85.77, for a total value of $299,937.69.
  • On Thursday, February 1st, Robert Azelby sold 4,167 shares of Juno Therapeutics stock. The shares were sold at an average price of $85.78, for a total value of $357,445.26.
  • On Monday, January 22nd, Robert Azelby sold 102,539 shares of Juno Therapeutics stock. The shares were sold at an average price of $86.25, for a total value of $8,843,988.75.
  • On Monday, December 18th, Robert Azelby sold 1,816 shares of Juno Therapeutics stock. The shares were sold at an average price of $44.96, for a total value of $81,647.36.
  • On Thursday, November 2nd, Robert Azelby sold 6,666 shares of Juno Therapeutics stock. The shares were sold at an average price of $54.95, for a total value of $366,296.70.

Juno Therapeutics Inc (NASDAQ:JUNO) traded up $0.15 on Monday, hitting $85.84. The stock had a trading volume of 2,971,635 shares, compared to its average volume of 6,280,425. The firm has a market capitalization of $9,810.00, a PE ratio of -25.32 and a beta of 3.42. Juno Therapeutics Inc has a twelve month low of $19.62 and a twelve month high of $86.28. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.77 and a quick ratio of 4.77.

A number of hedge funds have recently modified their holdings of JUNO. The Manufacturers Life Insurance Company increased its position in Juno Therapeutics by 7.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after acquiring an additional 228 shares during the period. Advisor Group Inc. increased its position in Juno Therapeutics by 141.1% during the 3rd quarter. Advisor Group Inc. now owns 2,459 shares of the biopharmaceutical company’s stock worth $109,000 after purchasing an additional 1,439 shares during the period. QS Investors LLC acquired a new position in Juno Therapeutics during the 2nd quarter worth approximately $135,000. Bronfman E.L. Rothschild L.P. increased its position in Juno Therapeutics by 27,376.9% during the 3rd quarter. Bronfman E.L. Rothschild L.P. now owns 3,572 shares of the biopharmaceutical company’s stock worth $160,000 after purchasing an additional 3,559 shares during the period. Finally, State of Alaska Department of Revenue acquired a new position in Juno Therapeutics during the 4th quarter worth approximately $173,000. Hedge funds and other institutional investors own 68.90% of the company’s stock.

Several research firms recently commented on JUNO. Citigroup cut Juno Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, January 17th. Needham & Company LLC cut Juno Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, January 22nd. Maxim Group restated a “buy” rating and set a $56.00 price target on shares of Juno Therapeutics in a research report on Thursday, November 2nd. Wells Fargo & Co lowered Juno Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, December 12th. Finally, Wedbush lowered Juno Therapeutics from an “outperform” rating to a “neutral” rating in a research report on Wednesday, January 17th. Two equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and three have issued a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $51.20.

WARNING: “Juno Therapeutics Inc (NASDAQ:JUNO) EVP Robert Azelby Sells 29,131 Shares” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/12/robert-azelby-sells-29131-shares-of-juno-therapeutics-inc-juno-stock.html.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Insider Buying and Selling by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply